Hepatic Impairment Study for Lorlatinib in Cancer Patients

Stopped early · Phase 1

Conditions studied: Advanced Cancers

In brief

This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Key facts

Study ID

NCT03726333

Run by

Pfizer

People needed

1

Starts

2020-01-14

Expected to finish

2021-07-08

Last updated by the study team

2024-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective;
• Biliary obstruction with a biliary drain or stent;
• Neurologically stable gliomas and brain metastases;
• ECOG performance status of 0, 1, or 2;
• adequate bone marrow function;
• adequate pancreatic function;
• adequate renal function;
• female patients with negative pregnancy test

You may not qualify if…

• untreated esophageal varices; uncontrolled ascites;
• episodes of hepatic encephalopathy within the last 4 weeks;
• spinal cord compression; major surgery within 4 weeks prior to enrollment;
• radiation therapy within 2 weeks prior to enrollment;
• last anti-cancer treatment within 2 weeks prior to screening;
• previous high-dose chemotherapy requiring stem cell rescue;
• prior to irradiation to >25% of the bone marrow;
• gastrointestinal abnormalities;
• known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet;
• clinically significant bacterial, fungal or viral infections for non-liver cancer patients;
• clinically significant cardiovascular disease;
• uncontrolled hypertension; acute pancreatitis with predisposing characteristics;
• history of grade 3 or 4 interstitial fibrosis or interstitial lung disease;
• active hemoelysis or evidence of biliary sepsis;
• prior major gastrointestinal surgery;
• concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a narrow therapeutic index;
• concurrent use of CYP3A substrates with narrow therapeutic indices;
• prior treatment with lorlatinib; active bleeding disorder

Where it is running

• University of Colorado Denver CTO (CTRC) — Aurora, Colorado, United States
• University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) — Aurora, Colorado, United States
• University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado, United States
• University of Colorado Hospital, Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Investigational Drug Service — Atlanta, Georgia, United States
• The Emory Clinic — Atlanta, Georgia, United States
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
• Mays Cancer Center — San Antonio, Texas, United States
• University Health System — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.